Baxter (NYSE:BAX) announced late last week that it finally sealed the deal on its $3.9 billion acquisition of Swedish dialysis giant Gambro AB, closing the books on a deal months in the making.
Australian regulators just last week offered their blessing on the mega-deal, approving Baxter’s concessions to appease anti-trust concerns.
"The combination of these 2 respected renal leaders – Baxter and Gambro – will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies," Baxter chairman & CEO Robert Parkinson, Jr. said in prepared remarks. "Together, we will advance the state of dialysis care for patients with kidney disease worldwide."
Baxter had earlier offered to ditch its renal division in efforts to appease EuroZone regulators, who approved the merger last month. The Gambro AB buyout has also won approval from regulators in China, the Ukraine, Brazil, Canada, South Korea, Turkey and the U.S. before becoming official.
